Jones Financial Companies Lllp raised its stake in Sanofi (NASDAQ:SNY – Free Report) by 55.0% during the 4th quarter, ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi presented positive results ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the ...

Sanofi (NASDAQ:SNY – Free Report) – Equities researchers at Zacks Research lowered their Q2 2025 earnings estimates for Sanofi in a report issued on Wednesday, March 5th. Zacks Research analyst K.

Keybank National Association OH grew its stake in Sanofi (NASDAQ:SNY – Free Report) by 9.9% during the 4th quarter, Holdings Channel reports.The fund owned 10,105 shares of the company’s stock ...

Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

While markets sink, Regeneron Pharmaceuticals (NASDAQ:REGN) is up about 4%, or $30 on the day. Helping, the company and Sanofi (NASDAQ:SNY) just posted positive results from a pivotal ADEPT Phase ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...